Cargando…

Rate of Pathogenic Germline Variants in Patients With Lung Cancer

PURPOSE: Germline genetic testing (GGT) is now recommended for all patients diagnosed with ovarian or pancreatic cancer and for a large proportion of patients based solely on a diagnosis of colorectal or breast cancer. However, GGT is not yet recommended for all patients diagnosed with lung cancer (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sorscher, Steven, LoPiccolo, Jaclyn, Heald, Brandie, Chen, Elaine, Bristow, Sara L., Michalski, Scott T., Nielsen, Sarah M., Lacoste, Alix, Keyder, Emil, Lee, Hayan, Nussbaum, Robert L., Martins, Renato, Esplin, Edward D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2023
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681406/ https://www.ncbi.nlm.nih.gov/pubmed/37992258 http://dx.doi.org/10.1200/PO.23.00190

Ejemplares similares

Comparison of Germline Genetic Testing Before and After a Medical Policy Covering Universal Testing Among Patients With Colorectal Cancer
por: Moretz, Chad, et al.
Publicado: (2022)

Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer
por: Lincoln, Stephen E., et al.
Publicado: (2020)

CHEK2 Pathogenic Germline Variants in Patients With NSCLC
por: Sorscher, Steven
Publicado: (2022)

Universal Germline-Genetic Testing for Breast Cancer: Implementation in a Rural Practice and Impact on Shared Decision-Making
por: Shelton, Charles, et al.
Publicado: (2023)

Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer
por: Esplin, Edward D., et al.
Publicado: (2022)

Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional Study
por: Ossa Gomez, Carlos Andrés, et al.
Publicado: (2022)

Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo‐ECAG) ovarian study
por: Abdel‐Razeq, Hikmat, et al.
Publicado: (2022)

Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer
por: Coughlin, Sarah E., et al.
Publicado: (2022)

Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer
por: Whitworth, Pat W., et al.
Publicado: (2022)

Ashkenazi Jewish and Other White APC I1307K Carriers Are at Higher Risk for Multiple Cancers
por: Forkosh, Esther, et al.
Publicado: (2022)

Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study
por: Uson, Pedro L. S., et al.
Publicado: (2021)

Underdiagnosis of Hereditary Colorectal Cancers Among Medicare Patients: Genetic Testing Criteria for Lynch Syndrome Miss the Mark
por: Muller, Charles, et al.
Publicado: (2021)

The Impact of Proband Indication for Genetic Testing on the Uptake of Cascade Testing Among Relatives
por: Schmidlen, Tara J., et al.
Publicado: (2022)

Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort Study
por: Klek, Stefan, et al.
Publicado: (2020)

Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patients
por: Moon, Intae, et al.
Publicado: (2023)

Comparison of family health history to personal genomic screening for risk assessment of colon cancer
por: Heald, Brandie, et al.
Publicado: (2011)

Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
por: LoPiccolo, Jaclyn, et al.
Publicado: (2019)

Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study
por: Uson, P. L. S., et al.
Publicado: (2022)

Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma
por: Nassar, Amin H., et al.
Publicado: (2019)

Gastrointestinal polyposis and PTEN mutations: an under-acknowledged diagnostic criterion
por: Heald, Brandie, et al.
Publicado: (2010)

Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients
por: Espinel, Whitney, et al.
Publicado: (2022)

Universal Genetic Testing vs. Guideline-Directed Testing for Hereditary Cancer Syndromes Among Traditionally Underrepresented Patients in a Community Oncology Program
por: Jones, Jeremy C, et al.
Publicado: (2023)

Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study
por: Uson Junior, Pedro LS, et al.
Publicado: (2022)

Germline pathogenic variants in 786 neuroblastoma patients
por: Kim, Jung, et al.
Publicado: (2023)

The context-specific role of germline pathogenicity in tumorigenesis
por: Srinivasan, Preethi, et al.
Publicado: (2021)

Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells
por: Kawabata, S, et al.
Publicado: (2012)

CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer
por: Adib, Elio, et al.
Publicado: (2021)

Prognostic value of PCR, IL-6 and IL-10 serum levels in determining postoperative complications after geriatric surgery in diabetic patients
por: Cudia, B, et al.
Publicado: (2010)

Characterization of pathogenic germline mutations in human Protein Kinases
por: Izarzugaza, Jose MG, et al.
Publicado: (2011)

Prevalence of Germline Pathogenic and Likely Pathogenic Variants in Patients With Second Breast Cancers
por: Yao K, Katharine A, et al.
Publicado: (2020)

Frequent cleft lip and palate in families with pathogenic germline CDH1 variants
por: Green, Benjamin L., et al.
Publicado: (2022)

A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis
por: Granville, Courtney A., et al.
Publicado: (2009)

Pathogenicity and Penetrance of Germline SDHA Variants in Pheochromocytoma and Paraganglioma (PPGL)
por: Maniam, Pavithran, et al.
Publicado: (2018)

The prevalence of germline DICER1 pathogenic variation in cancer populations
por: Kim, Jung, et al.
Publicado: (2019)

Germline pathogenic variants in unselected Korean men with prostate cancer
por: So, Min-Kyung, et al.
Publicado: (2022)

Prevalence of pathogenic germline variants in the circulating tumor DNA testing
por: Yamamoto, Yoshihiro, et al.
Publicado: (2022)

Evolutionary Origin of MUTYH Germline Pathogenic Variations in Modern Humans
por: Xiao, Fengxia, et al.
Publicado: (2023)

Germline pathogenic variants in HNRNPU are associated with alterations in blood methylome
por: Lee, Sunwoo, et al.
Publicado: (2023)

Evolutionary Origin of Human PALB2 Germline Pathogenic Variants
por: Chian, Jia Sheng, et al.
Publicado: (2023)

Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variants
por: de Andrade, Kelvin C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b60gtj35t742th84396j73dp7h